logo-loader
viewTetraphase Pharmaceuticals Inc

Tetraphase Pharmaceuticals shares boosted by positive Phase 3 trial data

The biopharma’s study was evaluating the effects of its drug Xerava on patients with complicated intra-abdominal infections

Scientist in a lab
Tetraphase develops antibiotics for bacterial infections, including those resistant to multiple drugs

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) shares were on the rise following positive data from its Phase 3 clinical trial.

Shares of the Massachusetts-based company jumped 5.5% to $2.71 in Monday morning trading.

READ: Arix Biosciences forges partnership with Fred Hutch and Evotech to invest and create new drug companies focused on oncology

The biopharma’s study was evaluating the effects of its drug Xerava on patients with complicated intra-abdominal infections.

The company released its results at the Infectious Disease Society of America’s Infectious Disease Week in San Francisco.

“These data confirm the efficacy of XERAVA in a subgroup of cIAI patients who may be at higher risk for poor outcomes, and this new analysis comes at an exciting time as we make final preparations for the commercial launch of XERAVA in the coming weeks,” said CEO Guy Macdonald in the company’s press release.

Tetraphase also reported positive safety data from its multiple-ascending dose Phase 1 study of its intravenous drug TP-6076, an antibiotic developed for the treatment of serious and life-threatening bacterial infections.

The biopharmaceutical company develops novel antibiotics for bacterial infections, including those resistant to multiple drugs and viewed as public health threats by the World Health Organization and the Centers for Disease Control and Prevention.

Quick facts: Tetraphase Pharmaceuticals Inc

Price: 4.69 USD

NASDAQ:TTPH
Market: NASDAQ
Market Cap: $12.74 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Voyager Digital begins trading on the Canadian Securities...

Voyager Digital (CSE: VYGR) CEO Stephen Ehrlich joined Steve Darling from Proactive in Toronto to discuss the crypto company now listed on the CSE under the ticker VYGR.  Erhlich, who rang the opening bell of the CSE talks about the company, their token, and how they feel their...

18 hours, 48 minutes ago

2 min read